News & Partnering
Learn more about Imvax
For more detail on our progress, behind the scenes at Imvax, or opportunities to collaborate with us to advance the future of immunotherapy, dive in below.
Press releases
Imvax to Present Preclinical Data on IGV-001 Mechanism of Action at SITC Annual Meeting
PHILADELPHIA (October 21, 2021) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced a poster presentation at the 36th Annual Meeting of the Society... Read more
Imvax Appoints John M. Limongelli as Chief Legal Officer
PHILADELPHIA (September 16, 2021) — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of John M. Limongelli as the Company’s Chief... Read more
Imvax Further Strengthens Leadership Team with Appointment of Josh Muntner as Chief Financial Officer
PHILADELPHIA (August 9, 2021) — Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company’s chief financial officer effective... Read more
Imvax to present at UBS Global Healthcare Virtual Conference
PHILADELPHIA, PA (May 11, 2021) —Imvax, a clinical stage immuno-oncology company driven to transform patient treatment and outcomes with its novel technology platform, announced that John Furey,... Read more
Partnering with us
At Imvax, we know that making transformational therapies a reality takes many minds and different technologies working together. We welcome expressions of interest in collaborating to deliver a new generation of immunotherapies. We are a passionate, patient-focused, data-driven platform company.